Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled date : 2022 - 03 - 26 crawled time : 16:20 save search
AnaptysBio Appoints Daniel Faga As Interim Chief Executive Officer
Published: 2022-03-21 (Crawled : 16:20) - ir.anaptysbio.com
ANAB | $21.47 0.61% 0.61% 300K
|
Health Technology
|
| O: -2.75%
H: 1.75%
C: -2.41%
Alkermes to Participate in the Stifel 2022 CNS Days
Published: 2022-03-22 (Crawled : 16:20) - investor.alkermes.com
ALKS | News | $24.05 1.18% 1.16% 2.3M
|
Health Technology
|
| O: -0.73%
H: 2.12%
C: 0.69%
Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
| Email alert
Add to watchlist
clearance dermatitis skin phase 3
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
| Email alert
Add to watchlist
REGN | $901.27 0.8% 0.78% 470K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
| Email alert
Add to watchlist
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
| Email alert
Add to watchlist
olumiant phase 3
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.116 -2.18% 2.3K
|
Health Technology
| Email alert
Add to watchlist
REGN | $901.27 0.8% 0.78% 470K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
AMYT | $14.7 0.0% 2.4M
|
Health Technology
| Email alert
Add to watchlist
trial label positive phase 3
Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
| Email alert
Add to watchlist
edp1815 trial psoriasis phase 2
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
KRYS | $169.38 -0.42% -0.42% 150K
|
Health Technology
| Email alert
Add to watchlist
results phase 3
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.